What Coriell Life Sciences does

Coriell Life Sciences was a Philadelphia-based pharmacogenomics (PGx) clinical decision support software company founded in 2013 that developed evidence-based tools translating genetic test results into prescribing guidance. The company's core product analyzed 17 genes and 4 HLA alleles to help healthcare providers understand individual genetic responses to medications and optimize prescribing decisions, with primary therapeutic focus in psychiatry, cardiology, and oncology — areas with elevated adverse drug reaction risk. The technology addressed the trial-and-error nature of prescribing by layering pharmacogenomic interpretation onto existing clinical workflows.

The company operated as a B2B enterprise technology provider, distributing its decision support tools through OEM/embedded licensing agreements with healthcare and diagnostics partners. Its flagship relationship was with Quest Diagnostics, which launched a national pharmacogenomics testing service in September 2025 incorporating Coriell's clinical decision support layer. Revenue was generated through licensing and royalty arrangements rather than direct provider sales, and pricing was not publicly disclosed. CEO Scott Megill and co-founder Joseph P. Jarvis led the organization through its pre-acquisition period.

In September 2025, Coriell Life Sciences was acquired by InformedDNA, combining its PGx capabilities with InformedDNA's genetics expertise and technology platform and ending Coriell's independent operating history. The company had raised approximately $9.5 million in disclosed funding (2019) plus a follow-on round (2021) and employed 51–100 people at the time of acquisition. Note: Coriell Life Sciences is distinct from the Coriell Institute for Medical Research (coriell.org), an unrelated biobanking and research services organization; available sources do not clarify any ownership or operational linkage between the two entities.

Name

Coriell Life Sciences

Legal name

Coriell Life Sciences

Website

https://coriell.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

51–100 employees

Short description

Coriell Life Sciences is a Philadelphia-based pharmacogenomics company that develops clinical decision support software analyzing 17 genes and 4 HLA alleles to optimize medication prescribing across psychiatry, cardiology, and oncology for healthcare providers and diagnostics partners.

Ownership category

akta.pro rank

Product category

Pharmacogenomics Clinical Decision Support Software

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

akta.pro secondary industry

Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE)

Keywords

• Pharmacogenomics software
• Clinical decision support
• Precision medicine
• Genetic testing analysis
• Medication optimization

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Clinical Decision Support Licensing: Coriell Life Sciences generated revenue by providing pharmacogenomics clinical decision support technology that was integrated into healthcare providers' systems and diagnostic services. The technology analyzed genes and HLA alleles to help optimize medication prescribing decisions.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Coriell Life Sciences provides pharmacogenomics-powered clinical decision support tools that help healthcare providers interpret a patient's genetic profile and optimize medication prescribing decisions. The technology analyzes specific genes and HLA alleles to predict individual drug response, with applications across psychiatry, cardiology, and oncology specialties. The offering is delivered primarily through enterprise licensing arrangements that embed the decision support into larger diagnostic and clinical workflows.

Product overview

Coriell Life Sciences (now part of InformedDNA following acquisition) offered pharmacogenomics-focused clinical decision support tools. The company's core product provided genetic testing interpretation capabilities that analyze how individual genetic variations affect medication response, enabling personalized medication guidance across multiple therapeutic areas including psychiatry, cardiology, and oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Decision Support Tools for Pharmacogenomics Evidence-based clinical decision support software that interprets pharmacogenomic test results, analyzing 17 genes and 4 HLA alleles, to guide medication selection and dosing across psychiatry, cardiology, and oncology. Licensed to enterprise diagnostics providers for embedding in their pharmacogenomics testing services.

Quantifiable outcome

• Adverse drug reactions are the fourth leading cause of death in the United States

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Quest DiagnosticscoreStrategic or Co-development Partner · 9 September 2025Quest Diagnostics launched a pharmacogenomics testing service that incorporated clinical decision support tools powered by Coriell Life Sciences. The service analyzes 17 genes and 4 HLA alleles to help healthcare providers optimize prescribing decisions across psychiatry, cardiology, and oncology specialties.
• InformedDNAcoreStrategic or Co-development Partner · 1 January 2025Coriell Life Sciences was acquired by InformedDNA in 2025. The acquisition combined Coriell Life Sciences' pharmacogenomics capabilities with InformedDNA's genetics expertise and technology platform, strengthening InformedDNA's position in the precision medicine space.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Others

• Illumina: Illumina is a foundational sequencing and genomics-infrastructure provider whose technology underpins most PGx and clinical-genomics workflows. It is an enabling/adjacent peer rather than a direct competitor, but shapes the ecosystem in which Coriell's CDS operates.

Direct peers

• Molecular Health: Molecular Health provides a precision-medicine clinical decision support platform that analyzes genomic data to guide therapy selection, particularly in oncology. It overlaps directly with Coriell's CDS approach, especially in oncology pathways.
• YouScript (Genelex): YouScript (by Genelex) delivers pharmacogenomic testing with an interactive clinical decision support platform that flags drug-gene interactions for prescribers. It is a direct competitor in the embedded PGx CDS software category.
• Genomind: Genomind provides pharmacogenomic testing and decision support specifically focused on mental health / psychiatry prescribing. It competes head-to-head with Coriell's psychiatry-focused PGx CDS capabilities and uses a similar gene-panel + clinician-facing report model.
• OneOme: OneOme offers the RightMed pharmacogenomic test with integrated clinical decision support to help providers optimize medication selection. It is a direct functional peer to Coriell's PGx CDS platform, competing for the same provider and lab-partner channels.
• 2bPrecise (EHR-cone Healthspinout / Exact Sciences): 2bPrecise delivers a precision-medicine CDS layer that integrates genomic and pharmacogenomic insights into EHR workflows. It competes for the same embedded/EHR-integrated CDS slot that Coriell's tools target.

Broad incumbents

• Quest Diagnostics: Quest Diagnostics is both Coriell's enterprise customer (embedded into its PGx testing service) and a broad incumbent offering its own pharmacogenomic and genetic testing menu. It is the most direct commercial-partner comparable and a competitive threat at the lab-services layer.
• Myriad Genetics: Myriad Genetics offers genetic and pharmacogenomic testing products with associated decision-support reports across multiple therapeutic areas. It is a broad incumbent in the same clinical-genomics category with overlapping oncology and psychiatry content.
• InformedDNA: InformedDNA is a genetics-services and counseling organization that acquired Coriell Life Sciences in September 2025. Post-acquisition it is the corporate parent combining Coriell's PGx CDS with its own genetics-services platform, making it both parent and a broadened precision-medicine peer.
• Invitae: Invitae provides clinical genetic testing across many specialties with structured clinician reports that serve a decision-support function. It is a broader incumbent in clinical genomics that overlaps with Coriell's specialty coverage model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/corielllife

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coriell Life Sciences